SCHEMBL7237973

SCHEMBL7237973

CCOC(OCC)c1ccc(CN(C)Cc2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.44
POLB P06746 1/20 0.44
ALDH1A1 P00352 3/20 0.44
ACHE P22303 4/20 0.43
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
BCHE P06276 3/20 0.43
TSHR P16473 2/20 0.42
LMNA P02545 2/20 0.42
USP2 O75604 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
PYCR1 P32322 1/20 0.42
BLM P54132 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2046392 0.82 HRH3 (0.48) POLBALDH1A1ACHEBCHETSHR
SCHEMBL6203608 0.82 ALDH1A1 (0.45) KDM4ESMN1; SMN2POLBALDH1A1ACHE
SCHEMBL15105581 0.79 BCHE (0.49) KDM4ESMN1; SMN2ALDH1A1ACHEBCHE
SCHEMBL2041831 0.78 KMT2A (0.51) SMN1; SMN2POLBALDH1A1TSHRLMNA
SCHEMBL27191 0.78 ACHE (0.47) KDM4ESMN1; SMN2POLBACHEBCHE
SCHEMBL16980545 0.77 PYCR1 (0.61) KDM4ESMN1; SMN2ALDH1A1ACHECARM1
SCHEMBL13452933 0.76 CARM1 (0.46) KDM4EGAAMAPTSMN1; SMN2ALDH1A1
Dibemethine SCHEMBL10542007 0.75 ALDH1A1 (0.70) KDM4EGAAMAPTSMN1; SMN2POLB
SCHEMBL6394314 0.75 PTGS2 (0.57) MAPTACHEBCHELMNACYP3A4
Dibemethine SCHEMBL276863 0.75 ALDH1A1 (0.70) KDM4EGAAMAPTSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645989-B2 Antiinflammatory agents SMITHKLINE BEECHAM CORPORATION 2003-11-11 US disclosed
US-20030064997-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2003-04-03 US disclosed
US-6268370-B1 CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2001-07-31 US disclosed
US-5916891-A CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1999-06-29 US disclosed
US-5686455-A Imidazole derivatives and their use as cytokine inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1997-11-11 US disclosed
US-5656644-A CYTOKINE SUPPRESSORS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-12 US disclosed
EP-0623126-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1994-11-09 EP disclosed
WO-1993014081-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1993-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064997-A1 Novel compounds BRD4, BRDT, HDAC6 KDM4E 2100/4885GAA 1086/4885MAPT 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.